<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976469</url>
  </required_header>
  <id_info>
    <org_study_id>820903</org_study_id>
    <secondary_id>EUDRACT Number 2009-013131-38</secondary_id>
    <nct_id>NCT00976469</nct_id>
  </id_info>
  <brief_title>A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents</brief_title>
  <official_title>An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of Two Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the preferred dose of H1N1 pandemic influenza
      vaccine in a pediatric population, aged 6 months to 17 years, based upon assessments of
      immunogenicity and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the immune response to two different dose levels of a H1N1 pandemic influenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety of two different dose levels of a H1N1 pandemic influenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years</measure>
    <time_frame>Within 7 days after each vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Influenza</condition>
  <condition>Pandemic Influenza</condition>
  <arm_group>
    <arm_group_label>Dose A (3.75 µg HA antigen, 0.25 mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose B (7.5µg HA antigen, 0.5 mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)</intervention_name>
    <description>2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age</description>
    <arm_group_label>Dose A (3.75 µg HA antigen, 0.25 mL)</arm_group_label>
    <arm_group_label>Dose B (7.5µg HA antigen, 0.5 mL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011</intervention_name>
    <description>Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)</description>
    <arm_group_label>Dose B (7.5µg HA antigen, 0.5 mL)</arm_group_label>
    <other_name>Inflexal V</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent provided by subject's parent(s) / legal guardian(s)
             (according to national law)

          -  Written assent provided by subject according to age and capacity of understanding

          -  Subject is 9 to 17 years (Stratum A), 3 to 8 years (Stratum B), 12 to 35 months
             (Stratum C) or 6 to 11 months of age (Stratum D) at the time of screening

          -  Subject was born at full term of pregnancy (&gt;= 37 weeks) with a birth weight &gt;= 2 kg
             (Strata C and D) Subject / parent(s) / legal guardian(s) understand(s) the nature of
             the study and is / are willing to comply with the requirements of the protocol (e.g.
             return for follow-up visits, completion of the subject diary)

          -  If female of childbearing potential, subject presents with a negative urine pregnancy
             test within 24 hours prior to the first vaccination and agrees to employ adequate
             birth control measures for the duration of the study

          -  Subject is generally healthy, as determined by the investigator's clinical judgment
             through collection of medical history and the performance of a physical examination

          -  Subject is physically and mentally capable of participating in the study

        Exclusion Criteria:

          -  Subject has participated in another clinical study involving an investigational drug,
             biological product or device within 30 days prior to study enrollment or is scheduled
             to participate in another clinical study involving an investigational drug, biological
             product or device during the course of this study

          -  Subject has a history of exposure to A/H1N1/California/07/2009 virus or a history of
             vaccination with A/H1N1/California/07/2009 antigen or a closely related influenza
             virus antigen

          -  Subject has any inherited or acquired immune deficiency

          -  Subject currently has or has a recent history of significant neurological,
             cardiovascular or pulmonary (including asthma), hepatic, metabolic, rheumatic,
             autoimmune, hematological or renal disorder

          -  Subject has a history of testing positive for Human Immunodeficiency Virus (HIV),
             Hepatitis B Surface Antigen (HBsAg) or Hepatitis C Virus (HCV). No confirmatory
             testing for previous infection with these viruses will be conducted as part of this
             clinical study.

          -  Subject has a disease or is currently undergoing a form of treatment or was undergoing
             a form of treatment within 30 days prior to study entry that could be expected to
             influence immune response. Such treatment includes, but is not limited to systemic or
             high dose inhaled corticosteroids, radiation treatment, or other immunosuppressive or
             cytotoxic drugs.

          -  Subject has a history of severe allergic reactions or anaphylaxis

          -  Subject has a rash, dermatologic condition or tattoos which might interfere with
             injection site reaction rating

          -  Subject has received a blood transfusion or immunoglobulins within 90 days of study
             entry

          -  Subject has received any live vaccine within 4 weeks or inactivated vaccine within 2
             weeks prior to vaccination in this study Subject has functional or surgical asplenia

          -  Subject has a known or suspected problem with alcohol or drug abuse

          -  Subject or one of subject's parent(s) / legal guardian(s) is in a dependent
             relationship with one of the study team members. Dependent relationships include close
             relatives (i.e., children, siblings, partner/spouse, parents) as well as employees of
             the investigator or site personnel conducting the study

          -  Subject is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva-Maria Pöllabauer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Eferding</city>
        <state>Upper Austria</state>
        <zip>4070</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus (AKH) der Stadt Wien (General Hospital Vienna)</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Ettenheim</city>
        <zip>77955</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Kehl</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <name_title>Eva Maria Poellabauer, MD; Study Medical Director</name_title>
    <organization>Baxter Healthcare Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

